Citations

Clear

2960 citation(s) found for "Kim, In-Ho".

Multi‐Frequency Electrocochleography Results in Fewer Drop Alarms During Cochlear Implant Insertion
Espahbodi, Mana , Syed, Ali, Tu, Alex, Seidman, Michael D. , Danner, Christopher J., Allen, Kyle P., Bartels, Loren J., Ahsan, Syed F. , Voelker, Courtney C. J. , Deep, Nicholas L. , Chiffer, Rebecca C., Elrakhawy, Mohamed, Miller, Matthew W., Lin, Harrison W., Djalilian, Hamid R. , Angeli, Simon I., Kim, H J, Widick, Mark H., Stidham, Katrina R. , Patel, Neil S. , Koka, Kanthaiah , Hunter, Jacob B , Djalilian, Hamid R , Stidham, Katrina R , Gurgel, Richard Klaus , Doerfer, Karl W , Harris, Michael S , Danner, Christopher, Bartels, Loren Jay, Hunter, Jacob B. , Michaelides, Elias M. , Miller, Matthew W, Vivas, Esther , Angeli, Simón I., Hoa, Michael , Harris, Michael S.

Mayo Clinic

The Laryngoscope | May 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/lary.70592 | PMID 42084107 Get It

ABSTRACT Objective To evaluate intracochlear electrocochleography (ECochG) amplitude parameters during cochlear implantation (CI) using a novel multi‐frequency ECochG algorithm. Methods A multi‐institutional, prospective cohort study was performed at 18 high‐volume CI centers. The inclusion criteria were adults with sensorineural hearing loss and audiometric thresholds of ≤ 90 dB hearing level at 500 Hz undergoing CI with Advanced Bionics (Valencia, CA) Ultra 3D devices between 2024 and 2025. ECochG recordings were performed with simultaneous multi‐frequency stimulation of four frequencies between 125 and 4000 Hz during cochlear implant insertion. Concurrent multi‐frequency recording allowed extraction of amplitude and phase of each frequency individually. Post hoc analysis was performed to determine the difference in the number of drop alarms between single‐ and multi‐frequency ECochG. An ECochG amplitude drop of 6 dB was defined as a drop alarm. Insertion track patterns were compared between single‐ and multi‐frequency ECochG. Results One hundred ninety‐five ears were included. Mean number of drop alarms for the single‐frequency algorithm was 1.72 (95% CI: 1.52, 1.92; median 1) compared to 0.42 (95% CI: 0.31, 0.53; median 0) for multi‐frequency; p < 0.001. The number of Type C patterns (rise in amplitude during insertion followed by a drop) decreased with the multi‐frequency ECochG algorithm compared to the single‐frequency ECochG algorithm. The number of Type D patterns (no‐response) decreased, indicating that multi‐frequency ECochG generated more responses across the cochlea than single‐frequency ECochG. Conclusions A novel multi‐frequency ECochG algorithm during CI is associated with fewer drop alarms and altered insertion track patterns, which may provide a more accurate assessment of the cochlear microenvironment. Level of Evidence 3.
Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer
Bryant, John Michael, Sandoval, Maria, Putney, Ryan, Trivedi, Purvish , Katende, Esther N. , Fink, Angelina, Naqvi, Syeda Mahrukh, Kim, Youngchul, Yin, Vivian, Zhang, Jingsong, Park, J Y, Serna, Amparo, Lam, Nghi, Pow-Sang, J., Poch, Michael, Li, Roger, Manley, Brandon J, Naghavi, Arash, Torres-Roca, Javier, Grass, G Daniel, Kim, S, Latifi, Kujtim, Hunt, Dylan, Johnstone, Peter, Dhillon, Jasreman, Rodriguez, Paulo C, Jain, Rohit, Fernandez, Daniel C. , Yamoah, Kosj , Bryant, John Michael, Sandoval, Maria L., Putney, Ryan M. , Zhang, Jingsong , Serna, Amparo , Lam, Nghi B. , Poch, Michael , Manley, Brandon J, Naghavi, A.O. , Grass, G. Daniel , Latifi, Kujtim , Dhillon, Jasreman

Mayo Clinic

Journal for ImmunoTherapy of Cancer | May 4, 2026 | Volume: 14 | Issue: 5 | Pages: e013906

10.1136/jitc-2025-013906 | PMID 42082271 Get It

Background Grade group 5 (GG5) prostate cancer (PCa) carries a less favorable prognosis after standard-of-care (SOC) therapy, necessitating novel therapeutic approaches. High-dose rate brachytherapy (HDRBT) and androgen deprivation therapy (ADT) may modulate immune response in GG5 PCa, particularly in tumors with increased immune content. This study evaluated whether the addition of nivolumab to SOC was associated with improved disease control in patients with high-volume GG5 PCa, including those with oligometastatic disease. Methods In this non-randomized phase II trial, 31 patients with localized or oligometastatic GG5 PCa and >30% positive biopsy cores were evaluated between September 2018 and April 2021. Patients received four doses of nivolumab (240 mg every 2 weeks) beginning 4 weeks prior to HDRBT, alongside ADT, HDRBT, and external beam radiation. The primary endpoint was to evaluate whether the 2-year freedom from biochemical recurrence (FFBR) rate would exceed a prespecified historical control rate of 75%. Results Among the 31 patients, the median follow-up was 38.8 months (IQR 31.0–46.5 months). The addition of nivolumab to SOC RT with ADT was associated with a 2-year FFBR rate of 90.3% (95% CI 74.3% to 98.0%) (median FFBR not reached), exceeding the prespecified historical control rate of 75% (one-sided p value from binomial test=0.024). Definitive and probable nivolumab-related toxicity included 6.3% acute grade 2 and 6.3% acute grade 3 adverse events (AEs), with no grade 4+ AEs observed. A higher Decipher immunosuppression score at diagnosis correlated with early pathologic response (p=0.005) and was independently associated with time to metastatic failure (p=0.044). Conclusions Nivolumab combined with SOC was associated with encouraging FFBR in this high-risk GG5 PCa population and may represent a promising therapeutic intensification strategy. The Decipher immunosuppression score may serve as a predictive biomarker for response. These findings warrant further investigation in randomized trials.
A Survey-Based Study of Reproductive Health Practices by Immunologists of the Clinical Immunology Society in Patients with Inborn Errors of Immunity
Galant-Swafford, Jessica , Gans, Melissa, Huangpo, Tracy, Han, Sarah, Ward, Brant, Vinh, Donald, Chapdelaine, Hugo, Ackerman, Kevin, Rosenberg, Daniel, Squire, Jacqueline, Hobson, Jessica, Jongco, Art, Ahmed, Aisha, Ale, Hanadys, Kim, Vy, Barmettler, Sara , Piazza, Megan, Pachul, Jessica Willett, Fernandes, Monica, Nguyen, Ashley, Freeman, Catherine , Schutt, Madeline, Raje, Nikita , Bayer, Diana, Gunderman, Lauren, Trujillo, Vivian Hernandez-, Freeman, Alexandra, Gans, Melissa D. , Ward, Brant R. , Vinh, Donald Cuong , Chapdelaine, Hugo , Rosenberg, Daniel L. , Almarzooqi, Farida , Peng, Xiao P. , Ale, Hanadys , Kim, Vy Hong-Diep, Piazza, Megan S. , Gunderman, Lauren M. , Hernandez-Trujillo, Vivian Pilar, Hajjar, Joud

Mayo Clinic

Journal of Human Immunity | May 1, 2026 | Volume: 2 | Issue: CIS2026 | Pages: No page available

10.70962/cis2026abstract.20 Get It

Introduction Individuals with inborn errors of immunity (IEI) are increasingly reaching reproductive age, yet guidance on fertility preservation, genetic counseling, medication adjustments in pregnancy and breastfeeding, monitoring for complications, and multidisciplinary coordination is lacking. This joint effort between two committees of the Clinical Immunology Society (CIS), the Women of the Clinical Immunology Society (WCIS) and the Adult Immune Deficiency Committee (AID) survey aimed to characterize current reproductive care practices for IEI patients. Methods A survey was disseminated to 809 CIS members. The response rate was 6.43% (52 respondents). The 24-item questionnaire addressed management of pregnancy in IEI, medications adjustment, participation in hematopoietic stem cell transplant (HSCT) care and fertility preservation, and maternal/neonatal outcomes. Results Because survey items were optional, the number of respondents varies by question. Forty-two participants completed core items: 64% (27/42) allergists/immunologists, 71% (30/42) practicing at academic centers, and 48% (20/42) with &gt;50% immunology-focused practices. Most respondents (78%, 41/52) currently or previously cared for pregnant/planning IEI patients. Preconception counseling was common (90%, 37/41), yet only 2% (1/41) have access to a formal reproductive multidisciplinary team. Among clinicians involved in HSCT care, 45% (13/29) referred patients for fertility preservation. More than half, 52% (22/42), observed reduced fertility in IEI patients, and 56% (20/36) observed adverse maternal outcomes. Medication management varied: 61% (24/39) discontinued known teratogenic medications, and 64% (25/39) adjusted dosing during pregnancy. Regarding immunoglobulin replacement therapy, 79% adjusted dosing based on IgG levels and 42% increased dosing by trimester. Conclusions This CIS survey reveals practice variability and notable gaps in reproductive health support for individuals with IEIs. Due to the relatively low response rate, generalizability across providers and practice settings is challenging. However, the results of this survey suggest that although most clinicians provide preconception counseling and manage IgG and immunomodulatory therapy during pregnancy, formal multidisciplinary structures are rare. High rates of reported fertility concerns and maternal complications underscore the need for enhanced collaboration with obstetrics/gynecology and the development of structured, evidence-based, multidisciplinary guidelines for reproductive care in IEI. Tabular data are included as downloadable supplement files.
CD4+ T cells promote fibrosis during metabolic dysfunction–associated steatohepatitis
Valenzuela-Pérez, Lucía , Bayer, Rachel L., Manna, Dina F., Mishra, Shravan K., Washington, Alexander M. , Hassan, AbidM, Sidahmed, Malaz M., Ssali, Edward, Dinç, Ece Janet , Manwana, Benie K., Ibrahim, Ahmed, Guo, Qianqian, Herman, Adam, Graham, Rondell P., Gores, Gregory J., Starlinger, Patrick, Revelo, Xavier S. , Bamidele, Adebowale O., Hirsova, Petra, Kim Lee, Hyun Se , Hassan, Adna A, Revelo, Xavier , Manna, Dina Faeq , Lee, Hyun Se Kim , Pavelko, Kevin D. , Gores, Gregory J. , Starlinger, Patrick, Ibrahim, Samar H. , Kostallari, Enis , Bamidele, Adebowale O. , Valenzuela-Pérez, Lucía

Mayo Clinic

Hepatology | April 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001772 | PMID 42141897 Get It

Background and Aims: Unresolved inflammation and fibrosis are defining features of metabolic dysfunction–associated steatohepatitis (MASH), a progressive form of steatotic liver disease that can advance to cirrhosis and hepatocellular carcinoma. While innate immune mechanisms in MASH have been extensively characterized, the role of CD4 + T cells remains poorly understood despite their central function in orchestrating immune responses through effector and regulatory mechanisms. Approach and Results: Integrated single-cell proteomic, transcriptomic, and functional analyses were used to investigate the CD4 + T-cell landscape in murine and human MASH. We delineated a profound shift in the differentiation of intrahepatic and peripheral CD4 + T cells toward Th1, regulatory, and cytotoxic phenotypes in murine and human MASH. Notably, hepatic CD4 + T cells exhibited heightened effector activity and elevated secretion of proinflammatory cytokines, thus amplifying inflammatory signaling cascades. The CD4 + T-cell reprogramming in MASH also included the induction of the co-stimulatory receptor OX40. In parallel, OX40 ligand (OX40L)-expressing monocyte-derived macrophages and dendritic cells accumulated in MASH livers, establishing a feed-forward CD4 + T cell-myeloid activation loop. Therapeutic blockade of the OX40–OX40L axis, in turn, reversed liver pathology in mice with established MASH and reduced disease markers in an ex vivo human liver model. Furthermore, genetic depletion or functional inhibition of CD4 + T cells attenuated fibrosis, accompanied by decreased infiltration of monocyte-derived macrophages. Conclusions: These studies provide a comprehensive single-cell proteogenomic atlas of CD4 + T cells in MASH and identify an OX40-dependent CD4 + T cell-macrophage axis as a promising therapeutic target for the treatment of MASH and liver fibrosis.
Abstract TU118: Longitudinal Trajectories of Kidney Function in Heart Failure: A community study
Joo, Jungnam , Ganguli, Anirban , Bielinski, Suzette, Chamberlain, Alanna, Shearer, Joe, Roger, Veronique, Kim, Ji‐Eun , Bielinski, Suzette J. , Chamberlain, Alanna M. , Shearer, Joe, Roger, Véronique L.

Mayo Clinic

Circulation | April 30, 2026 | Volume: 153 | Issue: Suppl_1 | Pages: No page available

10.1161/cir.153.suppl_1.tu118 Get It

Introduction: Chronic kidney disease affects nearly half of heart failure (HF) patients, underscoring the importance of regular kidney function monitoring. However, longitudinal trajectories of kidney function in HF are not well characterized. Identifying clinical factors linked to long-term changes is critical for improving monitoring and informing early clinical decisions. Hypothesis: We hypothesized that longitudinal kidney function and its associations with clinical variables in HF patients differ from that of demographically similar comparators from the same community. Methods: We analyzed patients with validated HF from a community-based cohort and comparators individually matched to age and sex selected from participants in the Mayo Clinic Biobank cohort. Individuals with end-stage kidney disease, dialysis or kidney transplantation prior to enrollment were excluded. Serum creatinine-based estimated glomerular filtration rate (eGFR) from outpatient and inpatient visits was assessed from enrollment for up to 10 years of follow-up. The median of eGFR for 90-day intervals was used to estimate the follow-up eGFR (Figure 1) . We modeled percentage change from baseline and fit linear mixed-effect models with time, HF status, and their interaction to test whether the eGFR trajectories differed between the two groups. In addition, we examined the association between eGFR trajectories and clinical variables. Results: We studied 1182 HF patients and 825 comparators with at least three eGFR measurements. Median follow-up was 5 years (IQR: 3-10) for HF patients and 8 years (6-9) for comparators. In total, 16245 serum creatinine measurements from HF patients and 9858 from comparators were analyzed. Median age at enrollment was 76 years (67-84) for HF patients and 78 years (70-83) for comparators. A greater decline in percentage change in eGFR was observed in HF patients (-4.23%, 95% CI: -4.75 to -3.70% per year) than in comparators (-1.90%, 95% CI: -2.51 to -1.29% per year; P<0.001, Figure 2 ). Among HF patients, the decline in percentage change in eGFR was greater in the presence of diabetes, hyperlipidemia, or a higher comorbidity burden. Conclusions: In this community study, HF patients exhibited a greater percentage decline in eGFR compared to community comparators. Among HF patients, eGFR decline was more strongly associated with comorbidities—particularly metabolic risk factors—highlighting the relevance of the cardiovascular-kidney-metabolic syndrome in HF.
Disparities in Hearing Screening Practices in Minnesota Elementary Schools
Sajjadi, Autefeh , Kim, E S, Marcus, Kathryn S. , Todatry, Soorya, Hable, Nicholas, Roby, Brianne, Meyer, Abby C., Redmann, Andrew, Herd, Hannah, Maher, Rebecca, Chinnadurai, Siva, Nickel, Amanda , Jayawardena, Asitha , Kim, Elizabeth , Roby, Brianne , Todatry, Soorya , Hable, Nicholas, Roby, Brianne Barnett , Redmann, Andrew J. , Herd, Hannah

Mayo Clinic

The Laryngoscope | April 29, 2026 | Volume: 136 | Issue: 9 | Pages: 4064-4071

10.1002/lary.70566 | PMID 42049482 Get It

ABSTRACT Objective Identifying and addressing pediatric hearing loss is critical to supporting a child's development. School‐based hearing screening is a mainstay of timely identification of hearing loss. The objectives of this study were to characterize the current hearing screening practices in public, charter, and private elementary schools in Minnesota. Methods This was a cross‐sectional survey with data collected between March and June 2023. Surveys assessed the presence of standardized hearing screening processes and compliance with American Academy of Audiology (AAA) or Minnesota Department of Health (MDH) guidelines. Results About 146 public schools, 43 charter schools, and 60 private schools met inclusion criteria and responded to the survey. There was a statistically significant difference in the rate of standardized screening between school types ( χ 2 = 18.06; p < 0.001). Only 10.44% ( n = 26) of schools completed hearing screenings per AAA guidelines, and even fewer, 4.82% ( n = 12), completed hearing screenings according to MDH guidelines. The odds of screening per AAA or MDH guidelines were 3.50 times higher in charter schools compared to public schools (95% CI: 1.14, 10.73) and 4.61 times higher in private schools compared to public schools (95% CI: 1.73, 12.26). Conclusion There is a lack of standardization in hearing screening processes in Minnesota elementary schools. Adherence to screening per AAA or MDH recommendations is low in all types of elementary schools. Charter and private schools were more likely than public schools to screen per AAA or MDH guidelines. Overall, our data demonstrate an opportunity for improvement in school‐based hearing screening. Level of Evidence N/A.
Reducing empiric piperacillin-tazobactam use for patients with community-acquired intra-abdominal infections
Wilson, Claire , Epps, Kevin, Willis, Courney, Mendez, Julio, Kim, Joseph, Clair, Jesse St., Cowdell, J. Colt, Epps, Kevin L , St Clair, Jesse , Colt Cowdell, Jed , Mendez, Julio, Cowdell, Jed C.

Mayo Clinic

Antimicrobial Stewardship & Healthcare Epidemiology | April 28, 2026 | Volume: 6 | Issue: 1 | Pages: No page available

10.1017/ash.2026.10391 | PMID 42064231 Get It

Abstract Objectives: Community-acquired intra-abdominal infections (CA-IAIs) are a leading cause of US hospitalizations. Piperacillin-tazobactam is often used to empirically treat CA-IAIs, despite national guidelines recommending narrower-spectrum antibiotics for these infections. The overuse of broad-spectrum agents such as piperacillin-tazobactam contributes to antibiotic resistance, which poses serious public health challenges. This resident-led quality improvement initiative aimed to reduce unnecessary piperacillin-tazobactam use for treating CA-IAIs measured as DOT/1,000 patient-days by 10% without adversely affecting hospital length of stay (LOS). Methods: Using the DMAIC (define, measure, analyze, improve, control) framework, we identified barriers to appropriate antibiotic use and developed a treatment algorithm for CA-IAIs that included clear guidelines and exclusion criteria. This algorithm was disseminated to internal medicine residents and emergency department physicians along with educational sessions to highlight updated CA-IAI treatment recommendations, antibiotic resistance, and appropriate antibiotic ordering via the electronic health record. Antimicrobial stewardship pharmacists provided overnight support to assist with de-escalation. Data were collected over a 10-month period spanning 2 intervention phases. The primary outcome was piperacillin-tazobactam use, measured as days of therapy (DOT) per 1,000 patient-days and DOT per patient LOS. Mean LOS served as the balancing measure. Results: Piperacillin-tazobactam use was significantly reduced ( P < .001) after the interventions without increasing the mean LOS. Conclusion: This project raised awareness of antibiotic resistance and led to lasting improvements in reducing the inappropriate use of piperacillin-tazobactam to treat CA-IAIs, without affecting the mean LOS. This was attributed to the strong collaboration among a multidisciplinary team of infectious disease physicians, antimicrobial stewardship team members, residents, emergency department physicians, and faculty.
Liver transplantation is the major determinant of ≥10-year survival in patients with hepatocellular carcinoma
Rezaee‐Zavareh, Mohammad Saeid , Kim, Hyunseok, Luu, Michael, Ayoub, Walid, Kuo, Alexander, Trivedi, Hirsh D. , Wang, Yun, Vipani, Aarshi , Todo, Tsuyoshi , Voidonikolas, Georgios , Wisel, Steven A. , Brennan, Todd V. , Ferrone, Cristina, Kim, Irene , Kosari, Kambiz , Nissen, Nicholas, Parikh, Neehar D. , Singal, Amit G., Yang, Ju Dong , Ayoub, Walid S. , Parikh, Neehar D , Ahn, Joseph , (32846), Yun Wang, Steggerda, Justin A. , Singal, Amit G. , Yang, Ju Dong

Mayo Clinic

Hepatology Communications | April 27, 2026 | Volume: 10 | Issue: 5 | Pages: No page available

10.1097/hc9.0000000000000951 | PMID 42043868 Get It

Background: Hepatocellular carcinoma (HCC) has a poor long-term prognosis due to high recurrence and cirrhosis-related mortality, even after potentially curative treatments such as liver transplantation (LT), surgical resection, or ablation. This study aimed to identify factors associated with ≥10-year survival in HCC patients. Methods: A retrospective cohort study was conducted among HCC patients diagnosed between 2004 and 2022 using the National Cancer Database. Multivariable Cox regression was used to identify predictors of overall survival, and logistic regression was used to identify predictors of ≥10-year survival. Results: Among 249,600 HCC patients, 177,585 (71.2%) died within 5 years, 8613 (3.5%) died at 5–10 years, 54,988 (22.0%) were alive with <10 years of follow-up, and 8219 (3.3%) survived ≥10 years. LT, resection, and ablation were performed in 6.6%, 9.3%, and 11% of patients, respectively. Compared with ablation as the reference group, LT [adjusted odds ratio (aOR) 11.96, 95% confidence interval (CI): 11.27–13.29] and resection (aOR: 2.83, 95% CI: 2.57–3.08) increased the odds of ≥10-year survival, while non-curative treatments reduced the odds compared with ablation (aOR: 0.50, 95% CI: 0.47–0.55). Cox regression results were consistent with the logistic model, confirming the association. Decision tree analysis confirmed LT as the dominant determinant of long-term survival. Black individuals were associated with lower odds of ≥10-year survival (aOR: 0.88, 95% CI: 0.820–0.96) and decreased likelihood of receiving LT (aOR: 0.73, 95% CI: 0.55–0.96). Conclusions: LT offers the best chance of ≥10-year survival in HCC. Ensuring equitable access is essential, especially for Black patients who have lower transplant rates and worse outcomes.
Optimal Selection of the Effective Echo Time ( TE eff ) for T2 ‐Weighted Fast
Kim, Dahan , Pabi, Ronard, Borisch, Eric A. , Froemming, Adam T. , Grimm, Roger C., Hassanzadeh, Sara, Kawashima, Akira , Takahashi, Naoki , Thomas, John V. , Riederer, Stephen J. , Kido, Ayumu, Takahashi, Naoki , Riederer, Stephen J , Kawashima, Akira , Kido, Ayumu

Mayo Clinic

Journal of Magnetic Resonance Imaging | April 24, 2026 | Volume: 64 | Issue: 3 | Pages: 616-628

10.1002/jmri.70351 | PMID 42026845 Get It

ABSTRACT Background Clinical T 2 ‐weighted (T2W) MRI of prostate cancer (PCa) usually implements a 2D fast‐spin‐echo (FSE) sequence, but understanding the echo‐time‐dependent contrast behavior is not straightforward due to the complicated FSE signal evolution. Consequently, consensus‐based recommendations on the optimal effective echo time (TE eff ) to maximize contrast are lacking. Purpose To investigate the effect of TE eff on PCa lesion contrast in prostate T2W MRI. Study Type Phantom and in vivo prospective study. Subjects A standard MRI phantom and 53 prostate cancer patients (29 for image evaluation and 24 for quantitative lesion analysis). Field Strength and Sequence Multi‐slice T2W FSE sequence at 3 T acquired at multiple TE eff values. Assessment Three readers (13, 25, and 27 years' experience) evaluated TE eff = 100 ms versus 150 ms on diagnostic quality and reader preference. The effective T 2 relaxation rates ( T 2,eff ) were measured using FSE sequences in the phantom and used to predict the optimal TE eff maximizing T2W contrasts. From multi‐TE eff scans of subjects with suspected PCa, T 2,eff values of PCa lesions and healthy tissue were measured and used to calculate the optimal TE eff maximizing the lesion contrast. In vivo contrast metrics were measured as a function of TE eff . Statistical Tests Wilcoxon test of reader scores, with p < 0.05 defining statistical significance. Results No statistically significant difference was found in diagnostic quality between TE eff = 150 ms and 100 ms images, but all three readers significantly favored TE eff = 150 ms. Phantom experiments demonstrated that TE eff ‐dependent FSE signal progression can be characterized by T 2,eff values typically 40% longer than actual T 2 values, allowing accurate prediction of optimal TE eff within 2%–5%. Applied to PCa imaging, in vivo measurements indicated that effective T 2 relaxation times of the prostate are on average 1.5× longer than published T 2 values. Data Conclusion The benefits of TE eff = 150 ms versus 100 ms in prostate T2W FSE were supported by reader preference, phantom experiments, in vivo measurements, and analytic optimizations. Evidence Level 2. Technical Efficacy 2.
Risk Factors for Developing Candidemia after Gastrointestinal Perforation and/or Ischemia and Its Outcomes: A Matched Case–Control Study
Kim, Myeongji , Barrett, Kemar O. , Mahmoud, Khalid H., Strajina, Veljko , Shah, Aditya, Molina Garcia, Sofia , Barrett, Kemar O , Ranganath, Nischal , Garcia, Sofia Molina , Stevens, Ryan W. , LeMahieu, Allison

Mayo Clinic

Surgical Infections | April 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/10962964261445330 | PMID 42025448 Get It

Background: Candidemia is a serious complication after gastrointestinal (GI) perforation and/or ischemia, yet most evidence pools candidemia with intra-abdominal candidiasis (IAC). We sought candidemia-specific risk factors after GI perforation and/or ischemia and evaluated associated outcomes. Methods: We conducted a single-center, retrospective matched case–control study of adults undergoing emergency surgical procedure for GI perforation and/or ischemia and admitted to a surgical intensive care unit. Cases with candidemia during index admission were matched 4:1 to controls by age, Charlson Comorbidity Index, and surgical procedure year. Conditional logistic regression assessed pre-specified risk factors, and exploratory outcomes included mortality, length of stay, and days on invasive ventilation. Results: Twenty-four cases were matched to 99 controls. Factors identified to be independently associated with candidemia include the presence of IAC (adjusted OR [aOR]: 5.51, 95% CI: 1.61, 18.89; p = 0.007), upper GI injury (aOR: 4.28, 95% CI: 1.52–12.08; p = 0.006), and diffuse intra-abdominal contamination, compared with contained/none (aOR: 3.21, 95% CI: 1.06–9.74; p = 0.040). Among candidemia cases, species distribution was Candida albicans 41.7%, C. glabrata 33.3%, C. parapsilosis 12.5%, with single cases of C. tropicalis, C. krusei , and C. dubliniensis . Candidemia was associated with a longer hospital length of stay (+13.97 d; 95% CI: 0.90–27.04; p = 0.036), without significant differences in ICU stay, duration of invasive ventilation, or mortality. Conclusions: After GI perforation and/or ischemia, the risk of candidemia is highest in patients with upper GI injury and diffuse contamination, independent of IAC. These readily identifiable operative features may guide targeted surveillance and selective early antifungal strategies. Prospective validation is warranted.